Effect of Unani medicine Itrifal Ustukhudus in Nazla e Muzmin (Chronic Rhinosinusitis)

Clinical Validation of Unani pharmacopoeial formulation Itrifal Ustukhudus in Nazla e Muzmin (Chronic Rhinosinusitis)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016178

Enrollment

300

Registered

2018-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J329- Chronic sinusitis, unspecified Health Condition 2: null- Nazla e Muzmin (Chronic Rhinosinusitis)

Interventions

Intervention1: Itrifal Ustukhudus: 7 grams twice daily orally with lukewarm water daily Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of any in the age group of 19 to 60 years 2. Duration of disease >12 weeks 3. SNOT > 7

Exclusion criteria

Exclusion criteria: 1. Rhinosinusitis /Sinusitis of 2. Deviated Nasal septum 3.Nasal polyps 4. Local pathology such as mucocele, cyst, antrochoanal polyp, facial trauma, radiation injury, or birth defect • Diabetes mellitus and any other illness requiring long term treatment • Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Reduction of SNOT-22 scores Improvement in signs and symptoms of Zimad e Bars of Nazla e Muzmin (Chronic Rhinosinusitis)Timepoint: 6 weeks	—

Secondary

Measure	Time frame
Resolution of findings of X â??ray PNSTimepoint: at baseline and on completion of the protocol therapy ie after 6 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 4, 2026